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Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See
rights and permissions. Published by BMJ. INTRODUCTION: Opioid agonist treatment is effective for
opioid dependence and newer extended-release buprenorphine (BUP-XR) injections represent a
significant development. The Community Long-Acting Buprenorphine (CoLAB) study aims to evaluate
client outcomes among people with opioid dependence receiving 48 weeks of BUP-XR treatment, and
examines the implementation of BUP-XR in diverse community healthcare settings in Australia.
METHODS AND ANALYSIS: The CoLAB study is a prospective single-arm, multicentre, open-label trial of
monthly BUP-XR injections in people with opioid dependence. Participants are being recruited from a
network of general practitioner and specialist drug treatment services located in the states of New South
Wales, Victoria and South Australia in Australia. Following a minimum 7 days on 8-32 mg of sublingual
buprenorphine (±naloxone), participants will receive monthly subcutaneous BUP-XR injections
administered by a healthcare practitioner at intervals of 28 days (-2/+14 days). The primary endpoint is
participant retention in treatment at 48 weeks after treatment initiation. Secondary endpoints will evaluate
dosing schedule variations, craving, withdrawal, substance use, health and well-being, and client-reported
treatment experience. Qualitative and costing substudies will examine implementation barriers and
facilitators at the client and provider level. ETHICS AND DISSEMINATION: The study has received ethics
approval from the St Vincent's Hospital Sydney Human Research Ethics Committee (Ref. HREC/18/SVH/
221). The findings will be disseminated via publication in peer-reviewed journals, presentations at national
and international scientific conferences, and in relevant community organisation publications and forums.
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Abstract
Introduction Opioid agonist treatment is effective for opioid
dependence and newer extended-release buprenorphine
(BUP-XR) injections represent a significant development.
The Community Long-Acting Buprenorphine (CoLAB) study
aims to evaluate client outcomes among people with opioid
dependence receiving 48 weeks of BUP-XR treatment,
and examines the implementation of BUP-XR in diverse
community healthcare settings in Australia.
Methods and analysis The CoLAB study is a prospective
single-arm, multicentre, open-label trial of monthly BUP-XR
injections in people with opioid dependence. Participants are
being recruited from a network of general practitioner and
specialist drug treatment services located in the states of
New South Wales, Victoria and South Australia in Australia.
Following a minimum 7 days on 8–32 mg of sublingual
buprenorphine (±naloxone), participants will receive
monthly subcutaneous BUP-XR injections administered by a
healthcare practitioner at intervals of 28 days (−2/+14 days).
The primary endpoint is participant retention in treatment
at 48 weeks after treatment initiation. Secondary endpoints
will evaluate dosing schedule variations, craving, withdrawal,
substance use, health and well-being, and client-reported
treatment experience. Qualitative and costing substudies will
examine implementation barriers and facilitators at the client
and provider level.
Ethics and dissemination The study has received ethics
approval from the St Vincent’s Hospital Sydney Human
Research Ethics Committee (Ref. HREC/18/SVH/221).
The findings will be disseminated via publication in peer-
reviewed journals, presentations at national and international
scientific conferences, and in relevant community
organisation publications and forums.
Trial registration number NCT03809143
Protocol identifier CoLAB1801, V.4.0 dated 01 August
2019

For numbered affiliations see
end of article.
Correspondence to
Dr Michael Farrell;
michael.farrell@unsw.edu.au

Introduction
The two main medications used in opioid
agonist treatment (OAT), methadone and

Strengths and limitations of this study
►► This is an open-label trial with broad eligibility cri-

teria and flexible extended-release buprenorphine
(BUP-XR) dosing to more accurately reflect ‘real-
world’ clinical practice compared with previous randomised controlled trials.
►► The study will be conducted at a range of healthcare settings, including specialist opioid treatment
services and general practice, publicly and privately operated facilities, in metropolitan and regional
locations.
►► The sample size for the clinical intervention cohort
is relatively small with no comparison group; however, rich and detailed participant interview data will
be collected to evaluate the impact of BUP-XR on
people who are opioid dependent, including those
participants who discontinue treatment early.
►► This mixed-
method protocol (clinical intervention
cohort, qualitative research and costing) will focus
on the barriers and facilitators to implementation,
and will be used to inform models of care, clinical guidelines and training programmes for health
providers.

buprenorphine
(buprenorphine;±naloxone), are well established as safe and effective treatments for opioid dependence.1 2
OAT reduces illicit opioid use, crime, overdose, mortality risk and risk of HIV and hepatitis C virus (HCV) acquisition.3–5 Despite
these clear benefits, OAT carries some risks,
including adverse events, injection of medication intended for oral/sublingual administration, diversion and overdose.6–8
In response to these risks, supervised daily
dosing at a specialist clinic or pharmacy
is a feature of OAT in many countries1–4 at
least during the early stages of treatment.
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Attendance for daily dosing is burdensome for both
clients and service providers. People in treatment often
state that attendance for supervised dosing is restrictive on many aspects of daily life5 especially if significant travel time, cost and inconvenience is involved in
attending during limited clinic dosing hours. Additionally in Australia, people receiving OAT frequently pay the
costs of pharmacy dispensing fees6 which is a significant
burden for many clients, and also a barrier to treatment
access for many who are on income support payments
or disability support pensions.6 In some Australian jurisdictions, publicly funded specialist treatment services
cover the costs of supervised dosing so there is no cost to
the client, but this requires substantial staffing resources
that may be alternatively utilised for case management or providing health-related and/or psychosocial
interventions.
Recently developed extended-
release buprenorphine
(BUP-
XR) injections represent a significant development in OAT. They are administered subcutaneously
by a healthcare provider, releasing buprenorphine at a
controlled rate over the dosing interval. Currently formulations enable weekly9 10 or monthly administration.9–11
Early studies indicate that they provide rapid onset and
sustained release of buprenorphine,7 8 12 blockade at the
mu-opioid receptors minimising the euphorigenic opioid
effects of illicit opioid use,13 14 sustained reductions in
illicit opioid use and good treatment retention.15 16 Once-
monthly BUP-XR injections have been approved in the
USA, Canada, Australia17 and Europe, and once-weekly
BUP-XR injections have been approved in Australia18 19
and Europe.20
BUP-XR injections are expected to be associated with
several potential benefits. Eliminating the need to attend
for frequent dosing should increase convenience to
clients, and may reduce the costs to clients and providers.
Monthly BUP-XR injections may enhance treatment efficacy as a result of fewer missed doses, more consistent
buprenorphine plasma levels and improved treatment
exposure.21 BUP-
XR injections delivered by a healthcare professional may also reduce the diversion and use
via unintended routes of administration observed with
sublingual buprenorphine treatment.22–24
There is also substantial client interest in BUP-
XR.
A recent survey of people who used opioids regularly25
found that two-thirds of respondents believed BUP-XR
was a good treatment option for them. Interest was high
among those currently in OAT as well as those who were
not, with no differences according to prior methadone
vs buprenorphine experience.25 The most common
advantages endorsed by participants were less frequent
service attendance, ‘more time to do other things’ and
freedom to travel for work or holidays.25 Despite these
potential advantages, it is important to understand how
BUP-XR impacts on client outcomes and whether the
outcomes observed with BUP-XR are similar to sublingual
buprenorphine despite less frequent contact with treatment services.

Six-month retention on two BUP-XR formulations were
63% and 69%, respectively,15 16 in phase III clinical trials.
These retention levels are substantially higher than those
observed in routine treatment with sublingual buprenorphine,26 however, the extent to which these trials reflect
‘real-
world’ clinical practice is limited. The double-
blind placebo-controlled or active-controlled designs of
these trials required all participants to attend clinics on
a weekly basis, which does not reflect the likely routine
practice with injections of monthly BUP-XR. Clients were
a highly selected group, with a range of exclusions. There
are limited data available on the adherence, retention
and safety (adverse events) of BUP-XR injections over the
longer term, especially the potential for local injection
site complications. One open-label safety study with flexible dosing with either weekly or monthly BUP-XR over 48
weeks found high levels of retention (73.6% at 48 weeks)
and the treatment was well tolerated with a safety profile
consistent with that for sublingual buprenorphine.27
Additional studies conducted over such extended period
of treatment and adverse event monitoring are needed.
Implementing BUP-XR in the diverse range of treatment settings in Australia and many other countries also
presents challenges. Although specialist publicly funded
clinics with onsite pharmacies are available in some jurisdictions, the treatment models in other jurisdictions rely
predominantly on primary care prescribers and community pharmacies. Implementing BUP-XR in these diverse
settings has important service-level and system-level implications, including the development of new models of care
and new procedures for drug storage and administration.
The overarching aims of the Community Long-Acting
Buprenorphine (CoLAB) studies detailed in this protocol
are:
1. To evaluate the participant outcomes following the
implementation of a monthly injection of BUP-XR for
the treatment of opioid dependence in community-
based treatment settings with a focus on retention in
treatment, opioid and other illicit drug use, adherence
with the administration schedule and participants’ experiences of the implementation.
2. To develop and document the implementation of
a monthly injection of BUP-XR for the treatment of
opioid dependence with an emphasis on the feasibility
and practical clinical, regulatory and supply issues in
settings representative of Australian clinical practice.
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Methods and analysis
Study design
The CoLAB study is a prospective single-
arm, multicentre, open-label trial of monthly BUP-XR (Sublocade)
in people with opioid dependence, with qualitative and
costing substudies. The primary objective is to examine
treatment retention at 48 weeks following initiation
of BUP-
XR injections in clients with opioid dependence transferred from a stable dose of sublingual
buprenorphine.

Open access
A total of 100 people with opioid dependence will
be enrolled from seven Australian study site locations,
which include a mix of service providers in community
settings (eg, primary care based general practitioners)
and in specialist clinic settings. Sites were selected to be
representative of the range of treatment service models
typical in Australia, to facilitate efficient capture of implementation issues. All site principal investigators (PIs)
are current OAT prescribers, either addiction specialists
(n=6) or general practitioners with experience in delivering OAT (n=1), and were provided additional training
by the study team on BUP-XR administration and management. Participant recruitment commenced in May 2019
and is expected to reach completion in late 2019. Qualitative and costing substudies will also be conducted and
are described here in brief. The CoLAB study protocol
addresses all criteria in the 2013 Standard Protocol Items:
Recommendations for Interventional Trials guidelines
(online supplementary appendix 1, and study findings
will be reported in accordance with these criteria.
Participant eligibility
The study population is individuals with opioid dependence who are receiving 8–32 mg sublingual buprenorphine treatment (for at least 7 days), express interest in
receiving BUP-XR, and are deemed suitable for treatment with BUP-
XR by the site investigator. Eligibility
criteria are deliberately broad to allow enrolment of a
diverse group of participants. Anyone with significant,
medical or psychiatric conditions which would compromise compliance and/or client safety will be excluded.
Specific conditions of interest include hepatic disease
(Child-Pugh Class B or C), severe renal or respiratory
disease, or severe cognitive impairment or psychiatric
condition that impairs the ability to provide informed
consent (eg, psychosis, delirium, hypomania, severe
depression or suicidal ideation). While potential drug–
drug interactions for BUP-XR are similar to sublingual
buprenorphine, any participant with a history or presence
of allergic or adverse response to the ATRIGEL Delivery

System gel polymer component of Sublocade BUP-XR
will be excluded. Full eligibility criteria are described in
table 1.
Study schedule
The study consists of a screening phase (up to 4 weeks);
treatment intervention phase (48 weeks) and follow-up
at 4 weeks after the last dose of study medication, as
depicted in the study schema (figure 1):
(A) Screening: Following informed consent (please
refer to online supplementary file 1), screening assessments include: physical assessment, medical history,
substance use and related treatment history, urine pregnancy test, urine drug screening, concomitant medication, and eligibility confirmation. (B) Treatment: BUP-XR
treatment will be provided over 44 weeks, involving study
visits every 4 weeks. Each study visit consists: (1) clinical
and safety assessments (2) Administration of BUP-
XR
injection and (3) research interviews via telephone. (C)
Post-treatment follow-up: 4 weeks after the last dose of
BUP-XR, for collection of safety event and research interview data.
The procedures conducted at each visit throughout the
study are detailed in the CoLAB schedule of assessments
(table 2).
BUP-XR treatment
The protocol allows for participants to receive injections
of Sublocade scheduled 28 days apart (−2/+14 days;
figure 1). Sublocade contains a buprenorphine base in
a precipitation delivery system (ATRIGEL) of biodegradable polylactide-co-glycolide polymer and biocompatible
solvent (N-methyl-pyrrolidone), which, in contact with
aqueous interstitial fluid, solidifies in the subcutaneous
space to form a depot. This solid depot provides sustained
release of buprenorphine over a minimum of 28 days
through diffusion and polymer degradation.28 29
Participants will follow a dosing schedule aligned with
the Australian Sublocade product information.11 This
involves two Sublocade doses of 300 mg at baseline and

Table 1 Participant inclusion and exclusion criteria for the CoLAB study
Inclusion criteria

Exclusion criteria

►► Aged 18–65 years
►► Opioid-dependent currently receiving

►► Currently lactating or pregnant, or of childbearing potential and not willing

treatment
►► Has been receiving 8–32 mg sublingual
buprenorphine±naloxone tablets/film for at
least 7 days
►► Negative pregnancy test at screening and
baseline in females of childbearing potential

to avoid becoming pregnant during the study

►► History or presence of allergic or adverse response (including rash or

anaphylaxis) to buprenorphine or the ATRIGEL Delivery System.

►► Significant, medical or psychiatric conditions which would compromise

compliance with the protocol and/or client safety. Specific conditions of
interest include hepatic disease (Child-Pugh Class B or C), severe renal
or respiratory disease, or severe cognitive impairment or psychiatric
condition that impairs the ability to provide informed consent.
►► Subjects who are currently participating in any other clinical study
involving investigational medication(s).
►► Inability or unwillingness to provide informed consent or abide by the
requirements of the study.

CoLAB, Community studies of Long-Acting Buprenorphine.
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Supplemental doses of up to 8 mg daily sublingual
buprenorphine for 14 days are permitted, however, after
the first 2 BUP-XR doses additional doses will require
approval by the study chief medical officer, who is available to provide clinical advice to site staff throughout
the study. Treatment is to be discontinued in the event
of pregnancy, non-adherence to dosing regimen (more
than 56 days between injections), participant removal of
the depot or medical deterioration in clinical condition
of the participant according to the site PI. Where BUP-XR
treatment is discontinued for any reason, individualised
advice is provided by the study chief medical officer, typically to reintroduce sublingual buprenorphine based on
first principles.

Figure 1 CoLAB study schema. CoLAB, Community studies
of Long-Acting Buprenorphine; GP, general practitioner; BUP-
XR, extended-release buprenorphine.

week 4, reflecting ‘loading’ doses that elevate plasma
buprenorphine levels. Thereafter (doses 3–12), doses
are flexible with either 100 or 300 mg every 4 weeks, as
decided by the site investigator in consultation with the
participant (figure 1). Relevant factors in dose consideration include client craving and withdrawal, client rating
of dose adequacy, opioid and other substance use, and
adverse events. In general, doses should be maintained
(on 100 mg or 300 mg) if no clinically significant opioid
withdrawal, cravings, or dose-related adverse events are
identified, and the patient is satisfied with his/her current
dose. Doses should generally be reduced from 300 mg to
100mg if the patient reports dose-related adverse events
(eg, sedation, lethargy, headaches, nausea), the patient
is seeking to ultimately withdraw from OAT, or the
patient reports the dose is ‘too high’. Doses should be
increased from 100 mg to 300 mg if the patient is not
achieving treatment goals (eg, persistent unsanctioned
opioid use, withdrawal symptoms or cravings), no dose-
related adverse events to buprenorphine are identified,
or the patient reports the dose is inadequate and there
are no significant clinical safety concerns. All injections
will be administered by a medical practitioner or nurse
trained to perform the task. The product is administered
by subcutaneous injection into the abdominal area only,
with the injection site rotated each dose to avoid potential
irritation.
4

Participant interviews
Participants will complete interviews via telephone at intervals of 28 days (±4 days) throughout the treatment period.
After the first BUP-XR dose, the interview schedule is
independent of the dosing schedule and participants who
discontinue treatment will remain in follow-up for interviews. The interviews are structured from a combination
of validated tools and additional questions developed by
the protocol steering committee (PSC), collecting client-
reported withdrawal, craving, substance use, overdose,
health service utilisation, work attendance, pain, quality
of life, and treatment satisfaction data. The questionnaires included in the interviews are described in table 2.
Participants are reimbursed AUD50 per completed interview as compensation for their time.
Outcome measures and analysis
The primary objective of the CoLAB trial is to examine
treatment retention at 48 weeks following initiation of
BUP-XR injections at intervals of 28 days (−2/+14 days) in
clients with opioid dependence transferred from a stable
dose of sublingual buprenorphine. Secondary objectives
include evaluation of dosing schedule variations, craving,
withdrawal, substance use, health and well-
being, and
client-reported treatment experience over the treatment
period. Study endpoints are described in table 3.
Safety event reporting
In addition to standard adverse event and serious
adverse event (SAE) data collection and reporting to
the ethics committee, regulatory authority and Indivior
pharmacovigilance, information on adverse events of
special interest (AESI) will be collected. AESI include:
pregnancy, buprenorphine overdose, severe hepatic
impairment, depot removal and severe precipitated
withdrawal. A medical monitor independent of UNSW,
the CoLAB study and Indivior will review all SAEs for
relatedness to BUP-XR and/or study participation. A
data safety monitoring board will review interim safety
data once the first 20 participants have reached month 6
of the study, with subsequent review commensurate with
its risk assessment.
Larance B, et al. BMJ Open 2020;10:e034389. doi:10.1136/bmjopen-2019-034389
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Table 2 CoLAB study schedule of assessments
Screening Treatment
0

4

Post-Tx

Study week

−4 to 0

Clinical assessments

 

8

12

16

20

24

28

32

36

40

44

48
 

Medical history and physical examination

X

 

Substance use and treatment history

X

 

Australian Treatment Outcome Profile (ATOP) X

 

Past 7 days sublingual buprenorphine dose

 

X

 

Eligibility confirmation*

 

X

 

Pregnancy test and contraception
counselling†

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Urine drug screening‡

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Concomitant medication review

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Adverse events

 

X

X

X

X

X

X

X

X

X

X

X

X

X

Dose adequacy

 

X

X

X

X

X

X

X

X

X

X

X

X

X

Clinical Opiate Withdrawal Scale

 

X

X

X

When participant reports BUP-XR dose inadequacy or withdrawal,
only

BUP-XR treatment

 

300 mg BUP-XR injection

 

X

100 or 300 mg BUP-XR injection§

 

    X

Telephone interviews

 

Demographics

 

X

Subjective Opiate Withdrawal Scale

 

X

Opioid Craving Scale

 

X

Dose Adequacy

 

ATOP

 

Overdose (self-report)

 

Health service utilisation

 

X

X

X

X

X

Australian Quality of Life four-dimension

 

X

X

X

X

X

Pain, Enjoyment, General Activity scale

 

X

X

X

X

X

Patient Health Questionnaire

 

X

X

X

X

X

WHO Absenteeism and Presenteeism

 

X

X

X

X

X

Treatment Satisfaction Questionnaire for
Medication

 

X

X

X

X

X

Treatment Perceptions Questionnaire

 

X

X

X

X

X

End of Treatment Questionnaire

 

Early Cessation Questionnaire

 

 
X

 
X

X

X

X

X

X

X

X

X

 
 
 

X
X

X

X

X

X

X

X

X

X

X

X

X
X

X

X

X

X

X

X

X

X

X

X

X
X

X

X

X

X

X

X

X

X

X

X

X
X

X

X

X

X

 

X

X

X

X

X

X

X

X

X
  When participant has discontinued BUP-XR treatment early,  
for any reason

 

*Includes routine clinical tests where needed to confirm eligibility, forexample, suspected severe hepatic or renal impairment.
†In women of childbearing potential.
‡At 3 selected sites, for validation of participant-reported drug use during interviews.
§From the 3rd BUP-XR injection, the dose prescribed can be either 100 or 300 mg, at the discretion of the treating Investigator.
BUP-XR, extended-release buprenorphine; CoLAB, Community studies of Long-Acting Buprenorphine.

Sample size
Existing clients of participating general practice and public
specialist drug and alcohol services will be approached
and following informed consent will be screened for
enrolment. A total of 100 participants will be enrolled
and receive at least one dose of BUP-XR. The sample will
allow estimation of the retention primary endpoint with
adequate precision, and evaluation of factors impacting
implementation at a variety of site types (specialist and

primary care; public and private). Estimates of retention
are based on phase III trials with BUP-XR products (estimated retention: 69%16; 95% CI 60.0% to 77.9%).
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Data management
Clinical data will be collected by participating sites and
entered into a web-based electronic case report form,
OpenClinica, an open-source clinical trial software for
electronic data capture and clinical data management.

Open access
Table 3 Primary and secondary endpoints of the CoLAB study
Primary objective

Primary endpoint

1. To examine extended-release buprenorphine BUP-XR)
treatment retention at 48 weeks

1.1 Proportion of participants retained in treatment at 48 weeks
following initiation of monthly depot buprenorphine injections.
Treatment retention is defined as remaining on active depot
buprenorphine medication at 48 weeks.
Secondary endpoint

Secondary objective
1. To examine BUP-XR treatment retention and
engagement in ongoing clinical care at 48 weeks

1.1 Proportion of participants retained in treatment at 48 weeks
following initiation of monthly depot buprenorphine injections and
engaged in ongoing clinical care. Treatment retention is defined
as remaining on active depot buprenorphine medication AND
completing a clinical assessment at 48 weeks.

2. To evaluate opioid craving, withdrawal, opioid and other 2.1 Change in clinically assessed (urinary drug screen) and client-
drug use
reported use of opioids
2.2 Change in clinically assessed (urinary drug screen) and client-
reported use of other drugs
2.3 Change in clinically assessed opioid craving
3. To evaluate client utilisation of buprenorphine
medication during the study, including BUP-XR dose
variation, adherence with dosing schedule and dose
supplementation

3.1 Percentage of participants who completed 12 injections (per
protocol) during the 48 week study period.
3.2 Percentage of participants requiring dose adjustments with
sublingual buprenorphine/buprenorphine-naloxone (and dose)
during treatment
3.3 Percentage of participants maintained on 300 mg per month
and 100 mg per month after the initial 2×300 mg injection
3.4 Mean duration of continuous treatment (weeks)
3.5 Reasons for drop-out among non-completers
3.6 Percentage of participants presenting to receive treatment
within 7 and 14 days of the next scheduled injection
3.7 Mean duration (days) between administered injections

4. To evaluate treatment safety and tolerability by
monitoring adverse events, and events of clinical interest
such as drug–drug interactions and pain management in
clients treated with BUP-XR

4.1 Percentage of participants with different types of ‘special
events of interest’
4.2 Percentage of participants with common adverse events
(reported in greater than 5%)
4.3 Percentage of participants with at least one severe or
potentially life threatening (grade 3 or 4) adverse event;
4.4 Percentage of participants withdrawn from treatment due to
unacceptable adverse events

5. To describe client-reported changes to health and social 5.1. Health service utilisation during treatment and estimated
well-being
costs (including client travel)
5.2. Hours worked in paid employment/study
5.3. Other changes in health and social well-being (as measured
by PEG, AQol-4D, ATOP client surveys)
6. To evaluate demographic, drug use and treatment
factors associated with treatment outcomes

6.1 Demographic, drug use and treatment characteristics
associated with treatment outcomes, for example, participant
retention

7. To evaluate client-reported experience of treatment

7.1 Client-reported treatment satisfaction measures

8. To examine BUP-XR treatment retention at 24 weeks

8.1 Percentage of participants retained in treatment at 24 weeks
following initiation of monthly depot buprenorphine injections.
Treatment retention is defined as remaining on active depot
buprenorphine medication at 24 weeks.
9.1 Using process measures identify the resource use at both
client and facility level

9. To document the cost of the treatment at different
settings

AQoL-4D, Australian Quality of Life four-dimension; ATOP, Australian Treatment Outcome Profile; CoLAB, Community studies of Long-Acting
Buprenorphine; PEG, Pain, Enjoyment, General Activity.

On-site monitoring and source data verification will be
completed at regular intervals by the sponsor for data
quality assurance and to ensure compliance with the

study protocol, International Conference on Harmonisation Good Clinical Practice (ICH-GCP) guidelines, ethics
approvals and sponsor standard operating procedures.
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Interviews will be conducted via telephone by UNSW
researchers, not involved in the participants’ clinical care
or study team located at the site. Data will be entered
by interviewers into the OpenClinica database. Multiple
contact methods (eg, mobile, email, social media
accounts) and those for participants’ family or friends will
be collected at baseline to facilitate intensive follow-up
and maximise retention in research interviews.
Qualitative research substudy
The qualitative substudy aims to examine factors impacting
BUP-XR implementation from the client, service provider,
clinician and policy-
maker perspective. Clients and
providers will be interviewed to explore clients’ interests,
expectations and experiences of receiving BUP-XR treatment, providers’ experiences of administering BUP-
XR
treatment in their service, and the organisational implications of implementing BUP-XR in service settings with
varied characteristics in terms of model of care, staffing
and policy. Qualitative interview data will be generated to
examine factors that clients, service providers, clinicians
and policy-
makers perceive as important in the implementation and delivery of BUP-XR for the treatment of
opioid dependence in community-based general practice
and specialist treatment settings; how this new treatment is
translated and made to work in its implementation contexts
and practices; how the introduction of this treatment may
impact treatment experience and shape service provision; and the possibilities of, and challenges posed by, this
new treatment. Purposive sampling will be used to recruit
consenting participants to participate in semistructured
interviews, conducted either in person (where possible) or
via telephone. Clients will be sampled to maximise diversity in gender, previous treatment experience and duration
on BUP-XR, including those who discontinue treatment
early. Interviews will capture a range of treatment timepoints including early BUP-XR experience soon after the
first dose, and follow-up interviews after at least 6 months
of treatment.

counselling or other healthcare costs, and any other
consumables/supplies. Costs will be obtained from state-
based salary and wage schedules, the Medicare Benefits
Scheme (diagnostics, consultations etc), and other standard unit costs where relevant. Any relevant overhead
and on-costs will be included. Monthly participant interviews will include collection of travel costs for BUP-XR
treatment, changes in work hours, and health service utilisation unrelated to the facility providing BUP-XR.
Patient and public involvement
Design of the CoLAB implementation study was informed
by a survey (n=402) evaluating patients’ priorities and
concerns regarding BUP-
XR.25 The research question,
study design, participant information sheet and survey
tools were reviewed by a community reference panel
which included individuals with a history of or current
drug use. Findings of the study will be disseminated
through a lay language summary posted to participants,
as well as publications distributed by advocacy agencies
representing people who use drugs.

Costing substudy
A costing substudy will be undertaken to evaluate the
impact of BUP-
XR treatment on both participating
services and participants. Resource use will be identified
at both the client and facility level and will include process
measures obtained through participant records (eg, medication charts), facility records (eg, appointment records)
and interviews with individual clinical team members (eg,
site PI, other treating staff and pharmacist)to document
procedures related to drug storage, drug administration
and client care. A bottom-
up or activity-
based costing
will be used, where each of the resources used will be
identified, measured and valued. This will include (but
is not limited to) the implementation or start-up costs;
staff training; treatment costs including time to prescribe,
order/transport medication, dispense and administer;
monitor drug storage (eg, refrigeration, temperature
incursions and wastage); cost of the medication; any

Discussion
BUP-XR injections have been established as efficacious
in licensing randomised controlled trials,15 16 however,
further data are limited.27 The CoLAB study will provide
data that reflect the ‘real world’ patient reported
outcome and experience measures in a context as close
to routine clinical care as possible, while also providing
important data on costs, client and provider perspectives,
and implementation facilitators and barriers. These data
will further inform models of care, clinical guidelines and
training programmes for health providers.
Although a recent survey conducted in Australia found
that the majority of people who use opioids regularly
anticipated that BUP-
XR would be a good treatment
option for them,25 criteria for effective BUP-XR client
selection have not been established. One concern is
that reduced clinician contact may impact treatment
outcomes for some clients, through loss of daily structure
and engagement with support services. Qualitative studies
of potential clients found that ‘longer’ BUP-XR formulations (eg, monthly or 6 monthly) were viewed as beneficial for clients who wanted to avoid thinking about drugs
and their networks of people who use drugs, wanted to
reduce stigma, and desired ‘normality’ and ‘recovery’.30
‘Shorter’ BUP-XR formulations (eg, weekly) were viewed
as beneficial to clients who were new to OAT, worried
about the safety and reliability/effectiveness of OAT,
want a ‘break’ from illicit opioids, and those who need
more regular contact with services to monitor/support
them.30 It is important to note, however, that the interest
in a hypothetical treatment may not translate into actual
experience and uptake of monthly BUP-XR injections.
Reduced frequency of clinic attendance also has implications for services providing OAT. While it may potentially free up resources for providing other services, the
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impact on clients’ other healthcare needs during BUP-XR
treatment is unknown. OAT for opioid dependence in
Australia is incorporated into a broader treatment model
of care involving regular clinical reviews, case management and psychosocial interventions, with services individualised for each client.1 In the CoLAB study, the
minimum frequency of scheduled clinical reviews with a
site investigator (or delegated clinician) is every 42 days.
Participation in psychosocial services (eg, counselling) is
encouraged, but not mandated, in the study protocol to
more accurately reflect ‘real world’ clinical practice. The
CoLAB study will provide important data on how clients
receiving monthly BUP-XR injections use psychosocial
and healthcare interventions in the periods between
injections.
The study will also explore implementation issues related
to management and administration of the BUP-XR medication. Sublocade must be stored and managed consistent with jurisdictional requirements for Schedule 8 (an
Australian classification of drugs of dependence that are
subject to additional regulatory controls regarding their
manufacture, supply, distribution, possession and use31).
Sublocade must also be stored under refrigerated conditions (2°C–8°C) and is supplied via cold chain to participating clinics, however, is stable at ambient temperature
for up to 7 days. The process of BUP-XR management,
including distribution, receipt, storage and temperature control, permits and accountability in accordance
with schedule 8 requirements will be documented to
identify barriers. Sites with and without onsite schedule
8 compliant refrigerated storage have been included to
examine these issues.
Although the study schedule of dosing and assessments
is designed to allow flexibility and mimic ‘real-world’ clinical scenarios, there are many that will not be evaluated
within the context of this research protocol. For example,
all participants must be stable on a daily dose of 8–32 mg
sublingual buprenorphine for at least 7 days immediately prior to the first BUP-XR injection. The study will,
therefore, not provide answers to clinical questions such
as initiation of Sublocade in patients using methadone
or illicit heroin, treatment of clients on low sublingual
buprenorphine doses (less than 8 mg daily) with BUP-
XR, and transfer of clients between the two current
BUP-
XR products (Sublocade and Buvidal). Clinical
guidelines regarding these specific scenarios have been
developed in Australia,31 with recommendations based
on the available evidence and expert consensus, though
further research is required. A further limitation is the
single arm design. The relatively small sample size and
lack of comparator limits the ability to evaluate effectiveness and cost-effectiveness of BUP-XR compared with the
sublingual buprenorphine standard of care; however, the
CoLAB study will provide important information on the
client retention, tolerability and acceptability of BUP-
XR, as well as the cost and key considerations involved
in integrating this formulation into clinical practice in
Australia.

The introduction of depot buprenorphine formulations is likely to have significant benefits for some clients
and their service providers. BUP-XR may not suit all OAT
clients, and some will prefer methadone or sublingual
buprenorphine treatment. Current treatment guidelines
recommend that medication choice is guided by client
factors such as prior experience with medications, adverse
events, drug–drug interactions, overdose risks and in some
cases logistic factors such as travel requirements. It is also
possible that prescribers may prefer BUP-XR where there
are concerns regarding a client’s non-
medical use (eg,
injecting, hoarding, diversion to others) of sublingual
buprenorphine, or a client has a number of risk factors for
unsupervised dosing that are difficult to mitigate, such as
homelessness, high-risk substance use, or history of medication diversion. Uptake and experience of clients will also
be impacted by the way in which the medication is incorporated into existing OAT policies (eg,31), education on
delivering BUP-XR for healthcare professionals, communication strategies and engagement of consumer groups
and peers. The CoLAB study will provide important data to
inform these activities.
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Ethics and dissemination
The study is sponsored and managed by the National Drug
and Alcohol Research Centre (NDARC), UNSW Sydney,
Australia. Oversight is provided by a PSC composed of clinical specialists in addiction medicine, epidemiologists with
expertise in opioid dependence and drug user research,
qualitative researchers, health economist, NDARC research
and clinical trials operational staff and representatives
from participating clinic sites. The protocol was informed
by a survey of over 400 consumers evaluating attitudes and
preferences for OAT. The PSC includes representatives
of community organisations advocating for people who
use drugs. This study has received ethics approval from
the St Vincent’s Hospital Sydney Human Research Ethics
Committee (Ref. HREC/18/SVH/221), and site specific
assessments have been approved by the local research
governance offices of participating sites. Future amendments will be similarly submitted for approval. The study
will be conducted in accordance with ICH-GCP guidelines,
the Declaration of Helsinki, and all applicable local ethical
and regulatory requirements. All participants must provide
written informed consent. The findings will be disseminated via publication in a peer-reviewed journal and relevant scientific conference presentations. In addition to the
primary clinical study report, we aim to publish a series of
secondary papers describing the various components of
the study, including implementation issues, qualitative and
costing substudies, and clinical guidance development. The
authors will disseminate findings to the affected community
by engaging organisations representing users.
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